2. Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России, ОООИ «Российская ревматологическая ассоциация «Надежда»». Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 250. Доступ: https://cr.minzdrav.gov.ru/schema/250_2 (дата обращения – 01.01.2023).

3. Smolen J.S., Landewe R.B.M., Bergstra S.A. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023; 82(1): 3–18.https://dx.doi.org/10.1136/ard-2022-223356.

4. Fraenkel L., Bathon J.M., England B.R. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. 2021; 73(7): 1108–23. https://dx.doi.org/10.1002/art.41752.

5. Neumann I. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis. Rheumatology (Oxford). 2020; 59(Suppl 3): iii60–iii67. https://dx.doi.org/10.1093/rheumatology/keaa035.

6. Gerard A.L., Simon-Tillaux N., Yordanov Y. et al. Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis. Eur J Intern Med. 2021; 88: 96–103.https://dx.doi.org/10.1016/j.ejim.2021.03.040.

7. Shirai T., Sato H., Fujii H. et al. The feasible maintenance dose of corticosteroid in Takayasu arteritis in the era of biologic therapy. Scand J Rheumatol. 2021; 50(6): 462–68. https://dx.doi.org/10.1080/03009742.2021.1881155.

8. Gracia-Tello B., Ezeonyeji A., Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017; 4(1): e000182.https://dx.doi.org/10.1136/lupus-2016-000182.

9. Strehl C., Bijlsma J.W.J., De Wit M. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an EULAR task force. Ann Rheum Dis. 2016; 75(6): 952–57. https://dx.doi.org/10.1136/annrheumdis-2015-208916.

10. Roubille C., Coffy A., Rincheval N. et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology. 2021; 60(8): 3738–46. https://dx.doi.org/10.1093/rheumatology/keaa850.

11. Yasir M., Goyal A., Sonthalia S. Corticosteroid adverse effects. In: StatPearls

12. Fardet L., Petersen I., Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011; 50(11): 1982–90. https://dx.doi.org/10.1093/rheumatology/ker017.

13. Bienvenu B., Ly K.H., Lambert M. et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016; 37(3): 154–65. https://dx.doi.org/10.1016/j.revmed.2015.12.015.

14. Maz M., Chung S.A., Abril A. et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021; 73(8): 1349–65. https://dx.doi.org/10.1002/art.41774.

15. Ассоциация ревматологов России. Федеральные рекомендации по диагностике и лечению системных васкулитов. 2013. Доступ: https://rheumatolog.ru/experts/klinicheskie-rekomendacii/ (дата обращения – 01.01.2023).

16. Hellmich B., Agueda A., Monti S. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020; 79(1): 19–30. https://dx.doi.org/10.1136/annrheumdis-2019-215672.

17. Huscher D., Thiele K., Gromnica-Ihle E. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009; 68(7): 1119–24. https://dx.doi.org/10.1136/ard.2008.092163.

18. Da Silva J.A.P., Jacobs J.W.G., Kirwan J.R. et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis. 2006; 65(3): 285–93. https://dx.doi.org/10.1136/ard.2005.038638.

19. Saag K.G., Koehnke R., Caldwell J.R. et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med. 1994; 96(2): 115–23. https://dx.doi.org/10.1016/0002-9343(94)90131-7.

20. Van Staa T.P., Leufkens H.G.M., Abenhaim L. et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6): 993–1000. https://dx.doi.org/10.1359/jbmr.2000.15.6.993.

21. Dejaco C., Brouwer E., Mason J.C. et al. Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities. Nat Rev Rheumatol. 2017; 13(10): 578–92. https://dx.doi.org/10.1038/nrrheum.2017.142.

22. Labarca C., Koster M.J., Crowson C.S. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: A retrospective cohort study. Rheumatology (Oxford). 2016; 55(2): 347–56. https://dx.doi.org/10.1093/rheumatology/kev348.

23. Broder M.S., Sarsour K., Chang E. et al. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. Semin Arthritis Rheum. 2016; 46(2): 246–52. https://dx.doi.org/10.1016/j.semarthrit.2016.05.009.

24. Мешков А.Д. Оптимизация определения активности и прогноза артериита Хортона. Диссертация на соискание ученой степени кандидата медицинских наук. 2015. Доступ: https://dissercat.com/content/optimizatsiya-opredeleniya-aktivnosti-i-prognoza-arteriita-khortona (дата обращения – 01.01.2023).

25. Proven A., Gabriel S.E., Orces C. et al. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Care Res. 2003; 49(5): 703–8. https://dx.doi.org/10.1002/art.11388.

26. Mahr A.D., Jover J.A., Spiera R.F. et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 2007; 56(8): 2789–97. https://dx.doi.org/10.1002/art.22754.

27. Jover J.A., Hernandez-Garcia C., Morado I.C. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 134(2): 106–14.https://dx.doi.org/10.7326/0003-4819-134-2-200101160-00010.

28. Braun J., Kastner P., Flaxenberg P. et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58(1): 73–81. https://dx.doi.org/10.1002/art.23144.

29. Stone J.H., Tuckwell K., Dimonaco S. et al. Trial of tocilizumab in giant-cell arteritis. 2017; 377(4): 317–28.https://dx.doi.org/10.1056/NEJMoa1613849.

30. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study. Ann Rheum Dis. 1986; 45(2): 136–38. https://dx.doi.org/10.1136/ard.45.2.136.

31. Karabayas M., Dospinescu P., Fluck N. et al. Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Rheumatol Adv Pract. 2020; 4(2): rkaa069. https://dx.doi.org/10.1093/rap/rkaa069.

32. Diamantopoulos A.P., Hetland H., Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: A case series. Biomed Res Int. 2013; 2013: 120638. https://dx.doi.org/10.1155/2013/120638.

33. Findeisen K.E., Sewell J., Ostor A.J.K. Biological therapies for rheumatoid arthritis: An overview for the clinician. Biologics. 2021; 15: 343–52. https://dx.doi.org/10.2147/BTT.S252575.

34. Sepriano A., Kerschbaumer A., Smolen J.S. et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020; 79(6): 760–70. https://dx.doi.org/10.1136/annrheumdis-2019-216653.

35. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019; 57(1): 8–16.

36. Crowson C.S., Matteson E.L., Myasoedova E. et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63(3): 633–39. https://dx.doi.org/10.1002/art.30155.

37. Watanabe R., Goronzy J.J., Berry G. et al. Giant cell arteritis: From pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol. 2016; 2(2): 126–37. https://dx.doi.org/10.1007/s40674-016-0043-x.

38. Филатова Е.Е., Чачило Е.В., Буланов Н.М. с соавт. Гигантоклеточный артериит в сочетании с ревматической полимиалгией: клинические проявления, диагностика и лечение. Клиническая фармакология и терапия. 2022; 31(1): 75–82.

39. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Актемра. РУ: ЛП-007556. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f9c192db-e07b-4d3c-b856-b5e6c7f1ab5b&t= (дата обращения – 01.01.2023).

40. Villiger P.M., Adler S., Kuchen S. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016; 387(10031): 1921–27.https://dx.doi.org/10.1016/S0140-6736(16)00560-2.

41. Specker C., Aringer M., Burmester G.R. et al. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clin Exp Rheumatol. 2022; 40(9): 1657–65.https://dx.doi.org/10.55563/clinexprheumatol/f7ff6q.

42. Мешков А.Д., Новиков П.И., Фомин В.В., Моисеев С.В. Гигантоклеточный артериит: трудности диагностики и методы лечения. Клиническая фармакология и терапия. 2014; 23(2): 48–54.

43. Schmidt W.A., Dasgupta B., Luqmani R. et al. A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis. Rheumatol Ther. 2020; 7(4): 793–810.https://dx.doi.org/10.1007/s40744-020-00227-2.

44. Мазуров В.И., Беляева И.Б., Самигуллина Р.Р. с соавт. Патогенетическая значимость применения гуманизированного моноклонального антитела к рецептору ИЛ6-α (тоцилизумаб) в терапии иммуновоспалительных заболеваний. Медицинский совет. 2020; (8): 102–112.

45. Насонов Е.Л., Мазуров В.И., Усачева Ю.В. Разработки отечественных оригинальных генно-инженерных биологических препаратов для лечения иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2017; 55(2): 201–210.

46. Мазуров В.И., Беляева И.Б., Самигуллина Р.Р. с соавт. Участие интерлейкина 6 в формировании патогенетических механизмов иммуновоспалительных заболеваний. Эффективная фармакотерапия. 2022; 18(8): 22–31.

47. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 16(5): 448–57.https://dx.doi.org/10.1038/ni.3153.

48. Smolen J.S., Feist E., Fatenejad S. et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022; 387(8): 715–26. https://dx.doi.org/10.1056/NEJMOA2201302.

49. Feist E., Fatenejad S., Grishin S. et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022; 81(12): 1661–68. https://dx.doi.org/10.1136/ard-2022-222630.

50. Zhang H., Watanabe R., Berry G.J. et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018; 137(18): 1934–48. https://dx.doi.org/10.1161/CIRCULATIONAHA.117.030423.

51. Koster M.J., Crowson C.S., Giblon R.E. et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022; 81(6): 861–67. https://dx.doi.org/10.1136/annrheumdis-2021-221961.

52. Ly K.H., Stirnemann J.O., Liozon E., Michel M.et al. Interleukin-1 blockade in refractory giant cell arteritis. Jt Bone Spine. 2014; 81(1): 76–78. https://dx.doi.org/10.1016/j.jbspin.2013.06.004.

53. Deshayes S., Ly K.H., Rieu V. et al. Steroid-sparing effect of anakinra in giant-cell arteritis: A case series with clinical, biological and iconographic long-term assessments. Rheumatology (Oxford). 2021; 61(1): 400–6. https://dx.doi.org/10.1093/rheumatology/keab280.

54. ClinicalTrials.gov. Giant Cell Arteritis and Anakinra Trial (GiAnT). ClinicalTrials.gov Identifier: NCT02902731.URL: https://clinicaltrials.gov/ct2/show/NCT02902731 (date of access – 01.01.2023).

55. Matteson E.L., Dasgupta B., Schmidt W.A. et al. A 2-week single-blind, randomized, 3-ARM proof of concept study of the effects of secukinumab (anti-il17 MAB), canakinumab (anti-IL-1 B MAB), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension to assess safety and effect duration. Arthritis Rheumatol. 2014; 66(Suppl): 391–92.

56. Institut de Recherches Internationales Servier. Abbreviated Clinical Study CL2-78989-012 Report Synopsis. 2016. URL: https://clinicaltrials.servier.com/wp-content/uploads/CL2-78989-012_synopsis_report.pdf (date of access – 01.01.2023).

57. Venhoff N., Schmidt W.A., Lamprecht P. et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: Study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials. 2021; 22(1); 543.https://dx.doi.org/10.1186/s13063-021-05520-1.

58. Tomelleri A., Rinaldi E., Campochiaro C. et al. Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis. Rheumatology (Oxford). 2023; 62(2): e24–e26. https://dx.doi.org/10.1093/rheumatology/keac416.

59. Conway R., O’Neill L., Gallagher P. et al. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Semin Arthritis Rheum. 2018; 48(3): 523–28. https://dx.doi.org/10.1016/j.semarthrit.2018.04.004.

60. Matza M.A., Fernandes A.D., Stone J.H., Unizony S.H. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken). 2021; 73(6): 893–97. https://dx.doi.org/10.1002/acr.24200.

61. Langford C.A., Cuthbertson D., Ytterberg S.R. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017; 69(4): 837–45. https://dx.doi.org/10.1002/art.40044.

62. Rossi D., Cecchi I., Sciascia S. et al. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Clin Exp Rheumatol. 2021; 39 Suppl 129(2): 125–128. https://dx.doi.org/10.55563/clinexprheumatol/l0hd9v.

63. Cid M.C., Unizony S.H., Blockmans D. et al. Efficacy and safety of mavrilimumab in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. 2022; 81(5): 653–61. https://dx.doi.org/10.1136/annrheumdis-2021-221865.

64. Study of the benefit of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness due to giant cell arteritis: CECIBO. Case Med Res. Published online 2000. https://dx.doi.org/10.31525/ct1-nct03841734.

65. Harkins P., Conway R. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline? Expert Opin Investig Drugs. 2022; 31(9): 921–32. https://dx.doi.org/10.1080/13543784.2021.1940949.

66. Hoffman G.S., Cid M.C., Rendt-Zagar K.E. et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007; 146(9): 621–30. https://dx.doi.org/10.7326/0003-4819-146-9-200705010-00004.

67. Seror R., Baron G., Hachulla E. et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014; 73(12): 2074–81. https://dx.doi.org/10.1136/annrheumdis-2013-203586.

68. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008; 67(5): 625–30. https://dx.doi.org/10.1136/ard.2007.082115.

69. Dasgupta B., Borg F.A., Hassan N. et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010; 49(8): 1594–97. https://dx.doi.org/10.1093/rheumatology/keq039a.

70. Mukhtyar C., Guillevin L., Cid M.C. et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009; 68(3): 318–23. https://dx.doi.org/10.1136/ard.2008.088351.

71. Bhatia A., Ell P.J., Edwards J.C.W. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005; 64(7): 1099–100. https://dx.doi.org/10.1136/ard.2005.036533.

72. Mulhearn B., Cooper E., Knights S. Rituximab fails to treat giant cell arteritis in a patient with ACPA-positive rheumatoid arthritis. Rheumatol Adv Pract. 2021; 5(1): rkab020. https://dx.doi.org/10.1093/rap/rkab020.

73. Mayrbaeurl B., Hinterreiter M., Burgstaller S. et al. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007; 26(9): 1597–98. https://dx.doi.org/10.1007/S10067-007-0684-0.

74. Sandovici M., Van Der Geest N., Van Sleen Y., Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open. 2022; 8(1): e001652. https://dx.doi.org/10.1136/rmdopen-2021-001652.